Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CeliAction: ALV003 in symptomatic celiac disease
NCT01917630Phase 2Unknown
- Sponsor
- Alvine Pharmaceuticals
- Start
- Aug 2013
- Primary completion
- Apr 2015
- Modality
- Replacement Enzymes
- Countries
- 6
01
Overview
A Phase 2 trial of latiglutenase in celiac disease, sponsored by Alvine Pharmaceuticals. Status: unknown.
02
Drugs
latiglutenase
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT01917630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01917630.